Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By sjmartinez • August 16, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. doi: 10.1164/rccm.202306-0944OC. PMID: 37364283.

Tags: COPD, dual PDE3 and PDE4 inhibitor, ensifentrine, nebulized therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Human papillomavirus vaccination in rural Malawi: Identifying factors associated with vaccine uptake using a community-based household survey

Moucheraud C, Kalande P, Chibaka S, Phiri K, Makwaya A, Duah M, Li M, Liu M, Hoffman RM, Phiri S. Human papillomavirus vaccination in rural[...]

Outcomes Following Minimally Invasive Surgery for Intracerebral Hemorrhage in the AHA Get With The Guidelines Registry

Murthy SB, Zhang C, Garton ALA, Mac Grory B, Shah S, Fonarow GC, Schwamm LH, Bhatt DL, Smith EE, Falcone GJ, Payabvash S, Ziai WC,[...]

A randomized controlled trial of meditation and health education on carotid intima-media thickness and major adverse cardiovascular events in Black men and women

Norris KC, Salerno J, Bairey Merz CN, Kaushik V, Gelleta S, Castillo A, Nidich S, Gaylord-King C, Schneider RH. A randomized controlled trial of meditation[...]